Evolution of nutritional status and survival in patients with cancer on tyrosine kinase inhibitors treatment.
Evolución nutricional y de la supervivencia en un grupo de pacientes oncológicos en tratamiento con inhibidores de tirosina quinasa.
Aged
Antineoplastic Agents
/ therapeutic use
Body Mass Index
Dietary Proteins
/ administration & dosage
Eating
/ drug effects
Energy Intake
Female
Humans
Kaplan-Meier Estimate
Linear Models
Male
Malnutrition
/ blood
Middle Aged
Neoplasms
/ blood
Nutritional Requirements
/ drug effects
Nutritional Status
/ drug effects
Prospective Studies
Protein-Tyrosine Kinases
/ therapeutic use
Quality of Life
Statistics, Nonparametric
Estado nutricional
Inhibidores de tirosina quinasa
Nutritional status
Supervivencia
Survival
Tyrosine kinase inhibitors
Journal
Endocrinologia, diabetes y nutricion
ISSN: 2530-0180
Titre abrégé: Endocrinol Diabetes Nutr (Engl Ed)
Pays: Spain
ID NLM: 101717565
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
08
04
2018
revised:
17
01
2019
accepted:
25
03
2019
pubmed:
7
6
2019
medline:
31
3
2020
entrez:
8
6
2019
Statut:
ppublish
Résumé
Treatment with oral antineoplastic agents known as tyrosine kinase inhibitors (TKIs) is new and, thus, little is known about their impact on nutritional status (NS), dietary intake, quality of life, and survival. The aim of this study was to provide information on these components in order to guide future nutritional recommendations. A prospective, observational study in adults who start treatment with TKIs, in whom NS was assessed using the Patient-Generated Subjective Global Assessment (PG-SGA), anthropometric measures, biochemical parameters, and dietary intake (24-hour dietary recall). The EORTC QLQ-C30 was used to assess quality of life. Nonparametric tests were used in statistical analysis, and survival was analyzed using Kaplan-Meier and log-rank curves. Of the overall sample, 21.7% had moderate malnutrition according to PG-SGA, and 74.2% moderate weight loss at 6 months, but no patient had BMI<18.5kg/m Treatment with TKIs does not appear to have a significant impact on NS and quality of life after 6 months of follow-up. Malnutrition should be prevented through individualized nutritional advice because it is related to shorter survival.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Treatment with oral antineoplastic agents known as tyrosine kinase inhibitors (TKIs) is new and, thus, little is known about their impact on nutritional status (NS), dietary intake, quality of life, and survival. The aim of this study was to provide information on these components in order to guide future nutritional recommendations.
PATIENTS AND METHOD
METHODS
A prospective, observational study in adults who start treatment with TKIs, in whom NS was assessed using the Patient-Generated Subjective Global Assessment (PG-SGA), anthropometric measures, biochemical parameters, and dietary intake (24-hour dietary recall). The EORTC QLQ-C30 was used to assess quality of life. Nonparametric tests were used in statistical analysis, and survival was analyzed using Kaplan-Meier and log-rank curves.
RESULTS
RESULTS
Of the overall sample, 21.7% had moderate malnutrition according to PG-SGA, and 74.2% moderate weight loss at 6 months, but no patient had BMI<18.5kg/m
CONCLUSIONS
CONCLUSIONS
Treatment with TKIs does not appear to have a significant impact on NS and quality of life after 6 months of follow-up. Malnutrition should be prevented through individualized nutritional advice because it is related to shorter survival.
Identifiants
pubmed: 31171456
pii: S2530-0164(19)30115-6
doi: 10.1016/j.endinu.2019.03.017
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Dietary Proteins
0
Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Journal Article
Observational Study
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
472-479Informations de copyright
Copyright © 2019 SEEN y SED. Publicado por Elsevier España, S.L.U. All rights reserved.